C07C 311/31
Having the sulfur atoms of the sulfonamide groups bound to acyclic carbon
Official title: having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
C07C311/31 (Having the sulfur atoms of the sulfonamide groups bound to acyclic carbon) appears on 102 US grants and 90 published applications in this corpus.
Search patents in C07C- Granted patents
- 102
- Published applications
- 90
- Assignees
- 68
- Inventors
- 310
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 5 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 6 | 0 |
| 2002 | 7 | 9 |
| 2003 | 6 | 3 |
| 2004 | 1 | 3 |
| 2005 | 3 | 4 |
| 2006 | 4 | 6 |
| 2007 | 2 | 5 |
| 2008 | 4 | 2 |
| 2009 | 2 | 5 |
| 2010 | 3 | 6 |
| 2011 | 1 | 1 |
| 2012 | 4 | 3 |
| 2013 | 4 | 2 |
| 2014 | 3 | 4 |
| 2015 | 2 | 1 |
| 2016 | 1 | 2 |
| 2017 | 3 | 3 |
| 2018 | 1 | 2 |
| 2019 | 1 | 5 |
| 2020 | 3 | 2 |
| 2021 | 4 | 5 |
| 2022 | 1 | 2 |
| 2023 | 5 | 3 |
| 2024 | 1 | 6 |
| 2025 | 4 | 4 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Amyloid targeting agents and methods of using the same22 Sep 2026US 12,741,949 B2Amydis, Inc.
- TES-based cationic lipids16 Jun 2026US 12,655,095 B2Translate Bio, Inc.
- Phenylalanine-based LAT1 inhibitors and uses thereof30 Sep 2025US 12,427,124 B1Maxymune Therapeutics, Inc.
- Inhibitors of the Wnt/beta-catenin pathway2 Sep 2025US 12,404,243 B2The Regents of the University of California
- Fatty acid analogues and methods of use25 Mar 2025US 12,258,324 B2
- Cyclohexyl or heterocycloalkyl beta-hydroxy alkyl amines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia17 Sep 2026US 2026/0274785 A1Atrogi AB
- Electrophilic reactive linkers for labeling of polypeptides and methods of use thereof25 Jun 2026US 2026/0174880 A1President and Fellows of Harvard College
- Phenylalanine-based lat1 inhibitors and uses thereof6 Nov 2025US 2025/0339388 A1Maxymune Therapeutics, Inc.
- Phenylalanine-based lat1 inhibitors and uses thereof16 Oct 2025US 2025/0319046 A1Maxymune Therapeutics, Inc.
- Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids28 Aug 2025US 2025/0270169 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Lipid derivatives80US 5,047,540 AShionogi & Co., Ltd. · 1991
- Lipid derivatives78US 5,138,067 AShionogi & Co., Ltd. · 1992
- α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors56US 6,248,775 B1G. D. Searle & Co. · 2001
- Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases44US 6,573,278 B2Bayer Aktiengesellschaft · 2003
- .alpha.-and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors43US 5,843,946 AG. D. Searle & Co. · 1998